What is Avalo Therapeutics Inc (AVTX) stock price today?

Avalo Therapeutics Inc (AVTX) currently trades at $13.20 per share. The stock has a market capitalization of $317.21M and a P/E ratio of —x.

Is AVTX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Avalo Therapeutics Inc has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Avalo Therapeutics Inc's revenue and earnings?

Avalo Therapeutics Inc has trailing twelve-month (TTM) revenue of $59000.00 with profit margins of 0.00%. Earnings per share (EPS) is $-5.84.

AVTX

Avalo Therapeutics Inc

NASDAQ: AVTX · HEALTHCARE · BIOTECHNOLOGY

$13.20

+2.64% today

Updated 2026-04-29

Market cap

$317.21M

P/E ratio

—

P/S ratio

5,376.53x

EPS (TTM)

$-5.84

Dividend yield

—

52W range

$3 – $21

Volume

0.8M

Market cap

$317.21M

P/E ratio

—

P/S ratio

5,376.53x

EPS (TTM)

$-5.84

Dividend yield

—

52W range

$3 – $21

Volume

0.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

5.0

Quality

C+

2.5

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$40.09

+203.71%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-14.25M

- Revenue declining -69.30% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$18.05M	$1.92M	$441000.00	$59000.00	$59000.00
Net income	$-41.66M	$-31.54M	$-35.13M	$-78.26M	$-13.72M
EPS	—	—	—	—	$-5.84
Free cash flow	$-26.85M	$-30.84M	$-49.06M	$-51.46M	$-14.25M
Profit margin	-230.78%	-1,639.50%	-7,965.76%	-132,642.37%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-16	DOYLE, MITTIE	Sale	19,500	—
2026-03-16	DOYLE, MITTIE	Sale	5,992	—
2026-03-16	DOYLE, MITTIE	Sale	25,492	$16.15

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
AVTX	$317.21M	23	2.7	2.5	5.0	5.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Avalo Therapeutics Inc trades at $13.20. Our Smart Value Score of 23/100 indicates the stock is weak. TTM revenue stands at $59000.00.

Frequently asked questions

What is Avalo Therapeutics Inc's stock price?

Avalo Therapeutics Inc (AVTX) trades at $13.20.

Is Avalo Therapeutics Inc overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Avalo Therapeutics Inc (AVTX)?

The analyst target price is $40.09, representing +203.7% upside from the current price of $13.20.

What is Avalo Therapeutics Inc's revenue?

TTM revenue is $59000.00.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio5,376.53x

ROE-72.40%

Beta0.94

50D MA$15.35

200D MA$14.03

Shares out0.02B

Float0.02B

Short ratio—

Avg volume0.8M

Performance

1 week+27.86%

1 month+2.60%

3 months+4.35%

YTD-2.20%

1 year—

3 years—

5 years—

Compare

AVTX vs LLY →AVTX vs JNJ →AVTX vs ABBV →Stock screener →